{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:44:52Z","timestamp":1789523092343,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.medj.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T14:53:03Z","timestamp":1721227983000},"page":"1275-1281.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study"],"prefix":"10.1016","volume":"5","author":[{"given":"Alan K.","family":"Percy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Neul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.06.007_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","article-title":"Global prevalence of Rett syndrome: systematic review and meta-analysis","volume":"12","author":"Petriti","year":"2023","journal-title":"Syst. Rev."},{"key":"10.1016\/j.medj.2024.06.007_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2024.06.007_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fncel.2014.00018","article-title":"Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in\u00a0vitro","volume":"8","author":"Baj","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.medj.2024.06.007_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","article-title":"Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms","volume":"26","author":"Bedogni","year":"2016","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.medj.2024.06.007_bib5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cne.22009","article-title":"Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks","volume":"514","author":"Belichenko","year":"2009","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.medj.2024.06.007_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and\u00a0women with Rett syndrome","volume":"55","author":"Motil","year":"2012","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.medj.2024.06.007_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.06.007_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.pediatrneurol.2015.02.007","article-title":"Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis","volume":"52","author":"Tarquinio","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.medj.2024.06.007_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mrdd.10020","article-title":"Clinical manifestations and stages of Rett syndrome","volume":"8","author":"Hagberg","year":"2002","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"10.1016\/j.medj.2024.06.007_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajmg.1320250506","article-title":"Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence","volume":"1","author":"Hagberg","year":"1986","journal-title":"Am. J. Med. Genet. Suppl."},{"key":"10.1016\/j.medj.2024.06.007_bib11","doi-asserted-by":"crossref","first-page":"345270","DOI":"10.1155\/2014\/345270","article-title":"Rett syndrome: coming to terms with treatment","volume":"2014","author":"Percy","year":"2014","journal-title":"Adv. Neurosci."},{"key":"10.1016\/j.medj.2024.06.007_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2015.12.021","article-title":"Caretaker quality of life in Rett syndrome: disorder features and psychological predictors","volume":"58","author":"Killian","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.medj.2024.06.007_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr. Open"},{"key":"10.1016\/j.medj.2024.06.007_bib14","series-title":"DAYBUE (trofinetide) [package insert]","year":"2023"},{"key":"10.1016\/j.medj.2024.06.007_bib15","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.06.007_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/WNL.0000000000203258","article-title":"Treatment with trofinetide shows benefit compared to placebo for the ability to communicate in individuals with Rett syndrome: a secondary analysis of the LAVENDER study (P13-9.006)","volume":"100","author":"Neul","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.06.007_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21678707.2023.2217328","article-title":"Recommendations for the management of diarrhea with trofinetide use in Rett syndrome","volume":"11","author":"Marsh","year":"2023","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.medj.2024.06.007_bib18","first-page":"1","article-title":"Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study","volume":"5","author":"Percy","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.medj.2024.06.007_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/1469-7610.00236","article-title":"The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome","volume":"43","author":"Mount","year":"2002","journal-title":"JCPP (J. Child Psychol. Psychiatry)"},{"key":"10.1016\/j.medj.2024.06.007_bib20","series-title":"NDA Application Number: 217026Orig1s000 (Trofinetide; DAYBUE), Clinical Reviews","year":"2019"},{"key":"10.1016\/j.medj.2024.06.007_bib21","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1177\/0883073815579707","article-title":"Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale","volume":"30","author":"Neul","year":"2015","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.medj.2024.06.007_bib22","series-title":"Patient-focused drug development: collecting comprehensive and representative input","year":"2018"},{"key":"10.1016\/j.medj.2024.06.007_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s11689-023-09502-z","article-title":"Top caregiver concerns in Rett syndrome and related disorders: data from the US Natural History Study","volume":"15","author":"Neul","year":"2023","journal-title":"J.\u00a0Neurodev. Disord."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:50:21Z","timestamp":1728661821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666634024002538"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.06.007","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}